Nöroimmünolojik Hastalıklarda Tanısal Yaklaşım

Lubetzki C. 150 years since Charcot’s lectures on multiple sclerosis. Lancet Neurol. 2018;17(12):1041. doi:10.1016/S1474-4422(18)30410-1

Hacohen Y, Mankad K, Chong WK, et al. Diagnostic algorithm for relapsing acquired demyelinating syndromes in children. Neurology. 2017;89(3):269-278. doi:10.1212/WNL.0000000000004117

Okuda DT, Lebrun-Frénay C. Radiologically isolated syndrome in the spectrum of multiple sclerosis. Mult Scler. 2024;30(6):630-636. doi:10.1177/13524585241245306

Luchesa Smith A, Sudarsan N, Hemingway C, Lim M. Diagnosis and management of multiple sclerosis and other relapsing demyelinating disease in childhood. Arch Dis Child. 2022;107(3):216-222. doi:10.1136/archdischild-2021-321911

Duignan SM, Hemingway CA. Paediatric acquired demyelinating syndromes. Paediatr Child Health (Oxford). 2019;29(11):468-475. doi:https://doi.org/10.1016/j.paed.2019.07.010

Hahn JS, Pohl D, Rensel M, Rao S. Differential diagnosis and evaluation in pediatric multiple sclerosis. Neurology. 2007;68(16 Suppl 2):S13-22. doi:10.1212/01.wnl.0000259403.31527.ef

Redenbaugh V, Fryer JP, Cacciaguerra L, et al. Diagnostic Utility of MOG Antibody Testing in Cerebrospinal Fluid. Ann Neurol. 2024;96(1):34-45. doi:10.1002/ana.26931

Carta S, Cobo Calvo Á, Armangué T, et al. Significance of Myelin Oligodendrocyte Glycoprotein Antibodies in CSF: A Retrospective Multicenter Study. Neurology. 2023;100(11):e1095-e1108. doi:10.1212/WNL.0000000000201662

Akaishi T, Takahashi T, Misu T, et al. Difference in the Source of Anti-AQP4-IgG and Anti-MOG-IgG Antibodies in CSF in Patients With Neuromyelitis Optica Spectrum Disorder. Neurology. 2021;97(1):e1-e12. doi:10.1212/WNL.0000000000012175

Yılmaz Ü. The diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in children. Explor Neuroprot Ther. 2024;4:38–54. https://doi.org/10.37349/ent.2024.00069.

Banwell B, Bennett JL, Marignier R, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. Published online January 2023. doi:10.1016/S1474-4422(22)00431-8

Waters PJ, Komorowski L, Woodhall M, et al. A multicenter comparison of MOG-IgG cell-based assays. Neurology. 2019;92(11):e1250-e1255. doi:10.1212/WNL.0000000000007096

Giri PP, Bhattyacharya S, Das D, Mukhopadhaya S. Acute disseminated encephalomyelitis: A clinical and neuroradiological profile of pediatric patients. Neurol India. 2016;64(6):1187-1192. doi:10.4103/0028-3886.193808

Massa S, Fracchiolla A, Neglia C, Argentiero A, Esposito S. Update on Acute Disseminated Encephalomyelitis in Children and Adolescents. Child. 2021;8(4). doi:10.3390/children8040280

Krupp LB, Tardieu M, Amato MP, et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler. 2013;19(10):1261-1267. doi:10.1177/1352458513484547

Tenembaum S, Chitnis T, Ness J, Hahn JS. Acute disseminated encephalomyelitis. Neurology. 2007;68(16 Suppl 2):S23-36. doi:10.1212/01.wnl.0000259404.51352.7f

da Rocha AJ, Barros BRC, Guedes BVS, Maia ACMJ. Idiopathic Inflammatory Demyelinating Disorders of the Central Nervous System in Children. Top Magn Reson Imaging. 2011;22(5):223-237. doi:10.1097/RMR.0b013e3182972c03

Hung PC, Wang HS, Chou ML, Lin KL, Hsieh MY, Wong AM. Acute disseminated encephalomyelitis in children: a single institution experience of 28 patients. Neuropediatrics. 2012;43(2):64-71. doi:10.1055/s-0032-1309309

Cole J, Evans E, Mwangi M, Mar S. Acute Disseminated Encephalomyelitis in Children: An Updated Review Based on Current Diagnostic Criteria. Pediatr Neurol. 2019;100:26-34. doi:10.1016/j.pediatrneurol.2019.06.017

Wong YYM, Hacohen Y, Armangue T, et al. Paediatric acute disseminated encephalomyelitis followed by optic neuritis: disease course, treatment response and outcome. Eur J Neurol. 2018;25(5):782-786. doi:10.1111/ene.13602

Huppke P, Gärtner J. A practical guide to pediatric multiple sclerosis. Neuropediatrics. 2010;41(4):157-162. doi:10.1055/s-0030-1267155

Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-173. doi:10.1016/S1474-4422(17)30470-2

Gaudioso CM, Mar S, Casper TC, et al. MOG and AQP4 Antibodies among Children with Multiple Sclerosis and Controls. Ann Neurol. 2023;93(2):271-284. doi:10.1002/ana.26502

Deisenhammer F, Bartos A, Egg R, et al. Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS task force. Eur J Neurol. 2006;13(9):913-922. doi:10.1111/j.1468-1331.2006.01493.x

Petzold A. Applying the 2017 McDonald diagnostic criteria for multiple sclerosis. Lancet Neurol. 2018;17(6):496-497. doi:10.1016/S1474-4422(18)30159-5

Jarius S, Wildemann B. The history of neuromyelitis optica. J Neuroinflammation. 2013;10:8. doi:10.1186/1742-2094-10-8

Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet (London, England). 2004;364(9451):2106-2112. doi:10.1016/S0140-6736(04)17551-X

Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-189. doi:10.1212/WNL.0000000000001729

Jarius S, Aktas O, Ayzenberg I, et al. Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis. J Neurol. 2023;270(7):3341-3368. doi:10.1007/S00415-023-11634-0

Hennes EM, Baumann M, Schanda K, et al. Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology. 2017;89(9):900-908. doi:10.1212/WNL.0000000000004312

Kunchok A, Chen JJ, Saadeh RS, et al. Application of 2015 Seronegative Neuromyelitis Optica Spectrum Disorder Diagnostic Criteria for Patients With Myelin Oligodendrocyte Glycoprotein IgG-Associated Disorders. JAMA Neurol. 2020;77(12):1572-1575. doi:10.1001/jamaneurol.2020.2743

Kuroda H, Fujihara K. Children with myelin oligodendrocyte glycoprotein antibodies-associated disease: relation of phenotypes to central nervous system myelin maturation. Dev Med Child Neurol. 2018;60(4):339-340.

Hacohen Y, Absoud M, Deiva K, et al. Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children. Neurol Neuroimmunol neuroinflammation. 2015;2(2):e81. doi:10.1212/NXI.0000000000000081

Waters P, Woodhall M, O’Connor KC, et al. MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol neuroinflammation. 2015;2(3):e89. doi:10.1212/NXI.0000000000000089

Xu Y, Meng H, Fan M, et al. A Simple Score (MOG-AR) to Identify Individuals at High Risk of Relapse After MOGAD Attack. Neurol Neuroimmunol neuroinflammation. 2024;11(6):e200309. doi:10.1212/NXI.0000000000200309

Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol. 2019;15(2):89-102. doi:10.1038/s41582-018-0112-x

de Mol CL, Wong Y, van Pelt ED, et al. The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults. Mult Scler. 2020;26(7):806-814. doi:10.1177/1352458519845112

Kidd D, Burton B, Plant GT, Graham EM. Chronic relapsing inflammatory optic neuropathy (CRION). Brain. 2003;126(Pt 2):276-284. doi:10.1093/brain/awg045

Lee H, Kim B, Waters P, et al. Chronic relapsing inflammatory optic neuropathy ( CRION ): a manifestation of myelin oligodendrocyte glycoprotein antibodies. Published online 2018:1-9.

Chalmoukou K, Alexopoulos H, Akrivou S, Stathopoulos P, Reindl M, Dalakas MC. Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis. Neurol Neuroimmunol neuroinflammation. 2015;2(4):e131. doi:10.1212/NXI.0000000000000131

Armangue T, Olivé-Cirera G, Martínez-Hernandez E, et al. Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. Lancet Neurol. 2020;19(3):234-246. doi:10.1016/s1474-4422(19)30488-0

Wegener-Panzer A, Cleaveland R, Wendel E-M, et al. Clinical and imaging features of children with autoimmune encephalitis and MOG antibodies. Neurol Neuroimmunol neuroinflammation. 2020;7(4). doi:10.1212/NXI.0000000000000731

Bruijstens AL, Lechner C, Flet-Berliac L, et al. E.U. paediatric MOG consortium consensus: Part 1 - Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol EJPN Off J Eur Paediatr Neurol Soc. 2020;29:2-13. doi:10.1016/j.ejpn.2020.10.006

Foiadelli T, Gastaldi M, Scaranzin S, Franciotta D, Savasta S. Seizures and myelin oligodendrocyte glycoprotein (MOG) antibodies: Two paradigmatic cases and a review of the literature. Mult Scler Relat Disord. 2020;41:102011. doi:10.1016/j.msard.2020.102011

Armangue T, Capobianco M, de Chalus A, Laetitia G, Deiva K. E.U. paediatric MOG consortium consensus: Part 3 - Biomarkers of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol EJPN Off J Eur Paediatr Neurol Soc. 2020;29:22-31. doi:10.1016/j.ejpn.2020.11.001

Venkatesan A, Tunkel AR, Bloch KC, et al. Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium. Clin Infect Dis. 2013;57(8):1114-1128. doi:10.1093/cid/cit458

Britton PN, Eastwood K, Paterson B, et al. Consensus guidelines for the investigation and management of encephalitis in adults and children in Australia and New Zealand. Intern Med J. 2015;45(5):563-576. doi:10.1111/imj.12749

Leypoldt F, Armangue T, Dalmau J. Autoimmune encephalopathies. Ann N Y Acad Sci. 2015;1338(1):94-114. doi:10.1111/nyas.12553

Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15(4):391-404. doi:10.1016/S1474-4422(15)00401-9

Cellucci T, Van Mater H, Graus F, et al. Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient. Neurol Neuroimmunol neuroinflammation. 2020;7(2). doi:10.1212/NXI.0000000000000663

Dalmau J, Graus F. Antibody-Mediated Encephalitis. N Engl J Med. 2018;378(9):840-851. doi:10.1056/NEJMra1708712

Wright MA, Trandafir CC, Nelson GR, Hersh AO, Inman CJ, Zielinski BA. Diagnosis and Management of Suspected Pediatric Autoimmune Encephalitis: A Comprehensive, Multidisciplinary Approach and Review of Literature. J Child Neurol. 2022;37(4):303-313. doi:10.1177/08830738211064673

Dahm L, Ott C, Steiner J, et al. Seroprevalence of autoantibodies against brain antigens in health and disease. Ann Neurol. 2014;76(1):82-94. doi:10.1002/ana.24189

Abboud H, Probasco JC, Irani S, et al. Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management. J Neurol Neurosurg Psychiatry. 2021;92(7):757-768. doi:10.1136/jnnp-2020-325300

Saiz A, Blanco Y, Sabater L, et al. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain. 2008;131(Pt 10):2553-2563. doi:10.1093/brain/awn183

Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10(1):63-74. doi:10.1016/S1474-4422(10)70253-2

Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12(2):157-165. doi:10.1016/S1474-4422(12)70310-1

Titulaer MJ, Höftberger R, Iizuka T, et al. Overlapping demyelinating syndromes and anti–N-methyl-D-aspartate receptor encephalitis. Ann Neurol. 2014;75(3):411-428. doi:10.1002/ana.24117

Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002;87(2):489-499. doi:10.1210/jcem.87.2.8182